BioNexus Gene Lab Corp.
BGLC
$5.30
-$0.12-2.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.47% | -10.28% | 11.03% | 3.00% | -23.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.47% | -10.28% | 11.03% | 3.00% | -23.07% |
| Cost of Revenue | 12.24% | -11.07% | 10.37% | 4.75% | -24.31% |
| Gross Profit | 27.47% | -5.89% | 15.98% | -7.85% | -15.01% |
| SG&A Expenses | 639.66% | 69.68% | -368.01% | -30.90% | -82.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -304.17% | 28.88% | 171.32% | -133.57% | 90.16% |
| Total Operating Expenses | 58.61% | 7.01% | 30.12% | -21.92% | -35.98% |
| Operating Income | -496.43% | -258.74% | -263.16% | 47.10% | 157.68% |
| Income Before Tax | -341.93% | -644.68% | -266.40% | 46.94% | 192.55% |
| Income Tax Expenses | -- | -- | -34.24% | -97.91% | 447.50% |
| Earnings from Continuing Operations | -409.49% | -500.48% | -212.90% | 48.44% | 176.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -409.49% | -500.48% | -212.90% | 48.44% | 176.78% |
| EBIT | -496.43% | -258.74% | -263.16% | 47.10% | 157.68% |
| EBITDA | -435.55% | -290.45% | -289.34% | 48.01% | 170.46% |
| EPS Basic | -404.35% | -490.97% | -211.51% | 51.86% | 162.93% |
| Normalized Basic EPS | -370.32% | -322.13% | -665.09% | 50.47% | 163.80% |
| EPS Diluted | -404.35% | -490.97% | -211.51% | 51.86% | 162.93% |
| Normalized Diluted EPS | -370.32% | -322.13% | -665.09% | 50.47% | 163.80% |
| Average Basic Shares Outstanding | 1.69% | 1.70% | 1.24% | 7.12% | 22.04% |
| Average Diluted Shares Outstanding | 1.69% | 1.70% | 1.24% | 7.12% | 22.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |